Is Barinthus Biotherapeutics plc (BRNS) overvalued? · rev $15.0M
Barinthus Biotherapeutics plc (BRNS) is a biotechnology company listed on US.
This page asks whether Barinthus Biotherapeutics plc (BRNS) looks expensive on cached numbers — not a short thesis.
Latest reported BRNS revenue for 2024-12-31 was $15.0M. Net income was -$61.2M. Revenue was up 1766.5% from 2023-12-31 to 2024-12-31. BRNS currently screens at market cap $38.2M.
BRNS currently screens at market cap $38.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BRNS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BRNS stock page for the full model, not this heading.
Not investment advice.